SDGR vs. TGTX, GRFS, LNTH, TLX, NUVL, AXSM, AKRO, PCVX, ADMA, and KRYS
Should you be buying Schrodinger stock or one of its competitors? The main competitors of Schrodinger include TG Therapeutics (TGTX), Grifols (GRFS), Lantheus (LNTH), Telix Pharmaceuticals (TLX), Nuvalent (NUVL), Axsome Therapeutics (AXSM), Akero Therapeutics (AKRO), Vaxcyte (PCVX), ADMA Biologics (ADMA), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry.
Schrodinger vs. Its Competitors
Schrodinger (NASDAQ:SDGR) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.
TG Therapeutics has a net margin of 10.13% compared to Schrodinger's net margin of -83.39%. TG Therapeutics' return on equity of 18.88% beat Schrodinger's return on equity.
Schrodinger currently has a consensus price target of $33.75, indicating a potential upside of 61.02%. TG Therapeutics has a consensus price target of $40.80, indicating a potential upside of 12.43%. Given Schrodinger's higher possible upside, equities research analysts clearly believe Schrodinger is more favorable than TG Therapeutics.
In the previous week, TG Therapeutics had 5 more articles in the media than Schrodinger. MarketBeat recorded 9 mentions for TG Therapeutics and 4 mentions for Schrodinger. TG Therapeutics' average media sentiment score of 0.83 beat Schrodinger's score of 0.64 indicating that TG Therapeutics is being referred to more favorably in the news media.
Schrodinger has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 1.91, indicating that its share price is 91% more volatile than the S&P 500.
79.1% of Schrodinger shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 8.6% of Schrodinger shares are owned by company insiders. Comparatively, 10.6% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
TG Therapeutics has higher revenue and earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
TG Therapeutics beats Schrodinger on 14 of the 16 factors compared between the two stocks.
Get Schrodinger News Delivered to You Automatically
Sign up to receive the latest news and ratings for SDGR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SDGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Schrodinger Competitors List
Related Companies and Tools
This page (NASDAQ:SDGR) was last updated on 7/3/2025 by MarketBeat.com Staff
